For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
19
views
27
references
 Top references
cited by
9
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      240
      similar
       All similar

      International Journal of Nanomedicine (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. Sign up for email alerts here.

      105,621 Monthly downloads/views I 7.033 Impact Factor I 10.9 CiteScore I 1.22 Source Normalized Impact per Paper (SNIP) I 1.032 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To minimize the side effects and the multidrug resistance (MDR) arising from daunorubicin (DNR) treatment of malignant lymphoma, a chemotherapy formulation of cysteamine-modified cadmium tellurium (Cys-CdTe) quantum dots coloaded with DNR and gambogic acid (GA) nanoparticles (DNR-GA-Cys-CdTe NPs) was developed. The physical property, drug-loading efficiency and drug release behavior of these DNR-GA-Cys-CdTe NPs were evaluated, and their cytotoxicity was explored by 3-[4,5-dimethylthiazol-2-y1]-2,5-diphenyltetrazolium bromide assay. These DNR-GA-Cys-CdTe NPs possessed a pH-responsive behavior, and displayed a dose-dependent antiproliferative activity on multidrug-resistant lymphoma Raji/DNR cells. The accumulation of DNR inside the cells, revealed by flow cytometry assay, and the down-regulated expression of P-glycoprotein inside the Raji/DNR cells measured by Western blotting assay indicated that these DNR-GA-Cys-CdTe NPs could minimize the MDR of Raji/DNR cells. This multidrug delivery system would be a promising strategy for minimizing MDR against the lymphoma.

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.

          Elizabeth Fox, Susan Bates (2007)
          P-glycoprotein actively transports structurally unrelated compounds out of cells, conferring the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific, noncompetitive inhibitor of P-glycoprotein. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both. In clinical trials, tariquidar is tolerable and does not have significant pharmacokinetic interaction with chemotherapy. In patients, inhibition of P-glycoprotein has been demonstrated for 48 h after a single dose of tariquidar. Studies to assess a possible increase in toxicity of chemotherapy and the impact of P-glycoprotein inhibition on tumor response and patient outcome are ongoing. Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer.
          Article 0 comments Cited 79 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nanotechnology applied to overcome tumor drug resistance.

            Zibin Gao, Linan Zhang, Yongjun Sun (2012)
            Emerging multidrug resistance (MDR) to chemotherapy is a major obstacle in successfully treating malignant diseases. Nanotechnology provides an innovative and promising alternative strategy compared to conventional small molecule chemotherapeutics to circumvent MDR. This review focuses on recent literature examples of nanotechnology applications to overcome MDR. The advantages and limitations of various nanotechnologies are discussed as well as possible approaches to overcome the limitations. Developing a practical nanotechnology-based drug delivery system requires further studies of the tumor microenvironment, the mechanisms of MDR to chemotherapy, the optimal dosage regimen of anticancer drugs and/or siRNA, the transport kinetics of nanocarriers in tumor stroma and the pharmacokinetics of drug-loaded nanocarriers within MDR tumor cells. Copyright © 2012 Elsevier B.V. All rights reserved.
            Article 0 comments Cited 76 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The risk of lymphoma in patients with psoriasis.

              Andrea B Troxel, Joel Gelfand, Daniel B Shin … (2006)
              Psoriasis is a common, chronic, inflammatory disease. Psoriasis has been hypothesized to be associated with an increased risk of lymphoma due to its pathophysiology, its treatments, or a combination of these factors. We performed a large population-based cohort study of the risk of lymphoma in psoriasis patients using the General Practice Research Database. We identified 153,197 patients with psoriasis and 765,950 corresponding subjects without psoriasis. Psoriasis patients who received a systemic treatment consistent with extensive disease were classified as severe (N=3,994) and those who did not receive systemic therapies were classified as mild (N=149,203). The analyses were adjusted for age, gender, and person-time using a Cox proportional hazards model. For mild and severe psoriasis patients, the respective adjusted relative risks for lymphoma and its subtypes were as follows: all lymphoma 1.34 (1.16, 1.54) and 1.59 (0.88, 2.89); non-Hodgkin's lymphoma 1.15 (0.97, 1.37) and 0.73 (0.28, 1.96); Hodgkin's lymphoma (HL) 1.42 (1.00, 2.02) and 3.18 (1.01, 9.97); cutaneous T-cell lymphoma (TCL) 4.10 (2.70, 6.23) and 10.75 (3.89, 29.76). Psoriasis is associated with an increased risk of lymphoma. The association is strongest for HL and CTCL. The excess risk of lymphoma attributed to psoriasis was 7.9/100,000 psoriasis patients per year. Although patients with psoriasis have an increased relative risk of lymphoma, the absolute risk attributable to psoriasis is low given that lymphoma is a rare disease and the magnitude of association is modest.
              Article 0 comments Cited 53 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Int J Nanomedicine
                Journal ID (iso-abbrev): Int J Nanomedicine
                Journal ID (publisher-id): International Journal of Nanomedicine
                Title: International Journal of Nanomedicine
                Publisher: Dove Medical Press
                ISSN (Print): 1176-9114
                ISSN (Electronic): 1178-2013
                Publication date Collection: 2016
                Publication date (Electronic): 18 October 2016
                Volume: 11
                Pages: 5429-5442
                Affiliations
                [1 ]Department of Hematology, Drum Tower Hospital, School of Medicine
                [2 ]Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing People’s Republic of China
                [3 ]School of Mechanical Engineering, Queen’s University Belfast, Belfast, UK
                Author notes
                Correspondence: Peipei Xu, Department of Hematology, Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, 210093, The People’s Republic of China, Tel +86 025 8310 5211, Fax +86 025 8310 5211, Email xu_peipei0618@ 123456163.com
                Yong Hu, Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of Engineering and Applied Sciences, Nanjing University, Nanjing, Jiangsu 210093, People’s Republic of China, Tel +86 025 8359 4668, Fax +86 025 8359 4668, Email hvyong@ 123456nju.edu.cn
                Article
                Publisher ID: ijn-11-5429
                DOI: 10.2147/IJN.S115037
                PMC ID: 5077128
                PubMed ID: 27799767
                SO-VID: 30ceaa82-6c31-4035-9fd9-381e9cdae858
                Copyright © © 2016 Zhou et al. This work is published and licensed by Dove Medical Press Limited
                License:

                The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

                History
                Categories
                Subject: Original Research

                ScienceOpen disciplines: Molecular medicine
                Keywords: daunorubicin,gambogic acid,cys-cdte qds,multidrug resistance,non-hodgkin’s lymphoma
                Data availability:
                ScienceOpen disciplines: Molecular medicine
                Keywords: daunorubicin, gambogic acid, cys-cdte qds, multidrug resistance, non-hodgkin’s lymphoma

                Comments

                Comment on this article

                scite_

                Similar content240

                See all similar

                Cited by9

                See all cited by

                Most referenced authors519

                See all reference authors